Dr. Nabila Rauf , Dr. Nabeela Yasmeen, Dr. Sobia Kaleem
Objective: To assess the vitamin B-12 Deficiency in type-II diabetics using Metformin. Material and method: This cross-sectional study was conducted at Department of Chemical Pathology, Sheikh Zaid Hospital, Rahim Yar Khan from March 2019 to September 2019 over the period of 6 months. Total 92 patients with type II diabetes mellitus using metformin were selected for this study. Vitamin B12 deficiency was assessed in selected patients. Results: In this cross-sectional study total 92 patients were selected. Mean Serum B-12 levels were 378.42±161.27 pg/ml and 488.90±147.02 pg/ml in metformin and non-metformin groups, respectively. The difference was statistically significant (p=0.001). The patients who were possibly deficient and definitely deficient were 15 (28.30%) and 5 (9.43%) in metformin group and were significantly more (p=0.006) than non-metformin group i.e. 4 (10.26%) and 0. The mean Toronto Neuropathy Score was statistically different (p<0.001) between metformin group (6.03±1.73) and non-metformin group (4.13±1.75). The patients who had mild neuropathy and moderate neuropathy were 23 (43.39%) and 5 (9.43%) in metformin group, while 6 (15.38%) and 2 (5.13%) in non-metformin group. Statistically, both the groups were significantly different (p=0.005). Conclusion: Findings of this study showed that metformin use for type II diabetes mellitus is strongly associated with vitamin B12 deficiency and worsening of already susceptible neuropathy. Keywords: vitamin B12, Type II diabetes mellitus, neuropathy.